During the EuroPCR 2017 of this year in Paris, I have had the privilege to present in 7 talks.
All the presentation will be shared during the next weeks.
STAY TUNED!
Presentations during the EuroPCR 2017 – 16-19 May 2017 Paris
EURO PCR 2017 – One year clinical outcome of percutaneous treatment with Sirolimus eluting balloons: Results from Nanolute prospective registry
During the EuroPCR 2017, I have presented theOne year clinical outcome of percutaneous treatment with Sirolimus eluting balloons: Results from Nanolute prospective registry.
Prospective, Multi‐center clinical registry real world, all comers patients at various indian Interventional Cardiology Sites. Clinical Follow-up at 1,6 and 12 Months.
Conclusion
SCB might constitute a new therapeutic option, considering the overall complexity of modern-era interventional cardiology.
The results of this registry, performed in indian patients, are encouraging, but deserve more complete clinical assessment in broader patients populations.
A synergistic DCB use with new-generation DES is intriguing
Here’s the presentation of the meeting
4 NANOLUTE' presentation
EURO PCR 2017 – AKI Matrix Late Breaking – Sub Study MATRIX
During the EuroPCR 2017, have been presented the Study AKI Matrix – Association between Radial or Femoral Access and Acute Kidney Injury in Patients with Acute Coronary Syndromes Undergoing Invasive Management.
The Objective of the study is to assess the incidence of AKI in patients with acute coronary syndrome (ACS) enrolled in the MATRIX-Access Trial.
Conclusion
– The results of this pre-specified substudy of the MATRIX Program show how a TR access results in fewer AKIs in ACS patients (both STE and not).
– Our findings are consistent in several subgroups.
Here’s the presentation of the meeting
3 AKI Matrix LBCT final
Twelve-month results of an unrestricted use of bioresorbable vascular scaffolds in a real world coronary artery disease population: primary outcome of the prospective RAI registry
During the EuroPCR 2017, I presented the results of the first year of Follow-Up for the RAI Registry, a spontaneous, multicenter, prospective data collection on consecutive patients undergoing BVS implantation in Italy.
The Objective of the Registry is to evaluate the long-term safety and efficacy of Absorb BVS within an unrestricted cohort of patients undergoing PCI. There have been enrolled 1505 Patients in 25 Italian Centers.
Conclusion
•The RAI registry represents a real world, contemporary
BVS population, with very few exclusion criteria.
• The population enrolled is extremely well treated
(predilatation, postdilatation).
• Current-era BVS use, according to specific and
standardized techniques of implantation, show good
clinical outcome in an unrestricted patient population at
mid-term follow up.
Here’s the presentation of the meeting
2 RAI 12m
Investigator Meeting EASTBOURNE Registry @Euro PCR 2017
During the EuroPCR 2017, I met 45 PI of the EASTBOURNE Registry to talk about the end point and the trend of the Study. There were PI from all around the world (Spain, China, Italy, Japan, England, India, etc.).
The EASTBOURNE Registry, thE All-comers Sirolimus-coaTed BallOon eURopeaN rEgistry, has been created to observe and evaluate the performance of a Sirolimus-
eluting Drug-Coated Balloon (SCB) for the treatment of any type of coronary lesions, including native vessel disease and in-stent restenosis.
The Registry has the following characteristics:
•Prospective, multicenter, spontaneous clinical registry
•Consecutive enrollment
•real world, all comers patients
Here’s the presentation of the meeting
1 EASTBOURNE Investigator Meeting